These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1597 related items for PubMed ID: 12853587

  • 1. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M, Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators.
    N Engl J Med; 2003 Jul 10; 349(2):146-53. PubMed ID: 12853587
    [Abstract] [Full Text] [Related]

  • 2. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.
    Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, Nicol P, Eklund SG, Nordlander S, Lärfars G, Leijd B, Linder O, Loogna E.
    N Engl J Med; 1997 Feb 06; 336(6):393-8. PubMed ID: 9010144
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.
    Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ, PREVENT Investigators.
    N Engl J Med; 2003 Apr 10; 348(15):1425-34. PubMed ID: 12601075
    [Abstract] [Full Text] [Related]

  • 6. Dalteparin versus unfractionated heparin in critically ill patients.
    PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group, Cook D, Meade M, Guyatt G, Walter S, Heels-Ansdell D, Warkentin TE, Zytaruk N, Crowther M, Geerts W, Cooper DJ, Vallance S, Qushmaq I, Rocha M, Berwanger O, Vlahakis NE.
    N Engl J Med; 2011 Apr 07; 364(14):1305-14. PubMed ID: 21417952
    [Abstract] [Full Text] [Related]

  • 7. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.
    Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, Kakkar AK, Prins M, Levine MN.
    J Clin Oncol; 2005 Apr 01; 23(10):2123-9. PubMed ID: 15699480
    [Abstract] [Full Text] [Related]

  • 8. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators.
    Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Moia M, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ageno W, Warfarin Optimal Duration Italian Trial Investigators.
    N Engl J Med; 2001 Jul 19; 345(3):165-9. PubMed ID: 11463010
    [Abstract] [Full Text] [Related]

  • 9. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
    Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV, CORTES Investigators. Clivarin: Assessment of Regression of Thrombosis, Efficacy, and Safety.
    N Engl J Med; 2001 Mar 01; 344(9):626-31. PubMed ID: 11228276
    [Abstract] [Full Text] [Related]

  • 10. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.
    Schulman S, Wåhlander K, Lundström T, Clason SB, Eriksson H, THRIVE III Investigators.
    N Engl J Med; 2003 Oct 30; 349(18):1713-21. PubMed ID: 14585939
    [Abstract] [Full Text] [Related]

  • 11. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.
    Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, Laporte S, Faivre R, Charbonnier B, Barral FG, Huet Y, Simonneau G.
    N Engl J Med; 1998 Feb 12; 338(7):409-15. PubMed ID: 9459643
    [Abstract] [Full Text] [Related]

  • 12. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis.
    Couturaud F, Julian JA, Kearon C.
    Thromb Haemost; 2001 Oct 12; 86(4):980-4. PubMed ID: 11686355
    [Abstract] [Full Text] [Related]

  • 13. Cancer-associated thrombosis: focus on extended therapy with dalteparin.
    Bick RL.
    J Support Oncol; 2006 Mar 12; 4(3):115-20. PubMed ID: 16553136
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.
    Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N.
    N Engl J Med; 1999 Sep 09; 341(11):793-800. PubMed ID: 10477777
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 80.